Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) Short Interest Up 131.1% in December

Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 600,079 shares, a growth of 131.1% from the November 30th total of 259,664 shares. Based on an average daily trading volume, of 1,176,791 shares, the short-interest ratio is presently 0.5 days. Approximately 4.8% of the company’s stock are sold short. Approximately 4.8% of the company’s stock are sold short. Based on an average daily trading volume, of 1,176,791 shares, the short-interest ratio is presently 0.5 days.

Institutional Investors Weigh In On Purple Biotech

An institutional investor recently bought a new position in Purple Biotech stock. Virtu Financial LLC bought a new position in shares of Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 48,993 shares of the company’s stock, valued at approximately $28,000. Virtu Financial LLC owned approximately 0.38% of Purple Biotech as of its most recent filing with the SEC. Hedge funds and other institutional investors own 9.64% of the company’s stock.

Analyst Ratings Changes

PPBT has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (e)” rating on shares of Purple Biotech in a research note on Monday, December 15th. Wall Street Zen downgraded Purple Biotech to a “strong sell” rating in a report on Friday, November 28th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Purple Biotech presently has a consensus rating of “Sell”.

Purple Biotech Price Performance

NASDAQ:PPBT opened at $0.71 on Friday. Purple Biotech has a 12 month low of $0.53 and a 12 month high of $5.20. The firm has a market capitalization of $9.07 million, a PE ratio of -2.21 and a beta of 0.60. The business’s fifty day moving average price is $0.76 and its 200 day moving average price is $1.40.

Purple Biotech Company Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage.